More evidence of the efficacy of Rituxan® for cancer therapy

Phase III Study Showed First-Line Maintenance Use of Rituxan Improved the Likelihood of People with Follicular Lymphoma Living without Their Disease Worsening || http://bit.ly/atkD7r || http://bit.ly/dd2UJg
clipped from www.gene.com

Rituxan is a therapeutic antibody that binds to a specific protein called CD20 found on the surface of cancerous and normal B-cells. In NHL and rheumatoid arthritis (RA), Rituxan works with the body's own immune system to eliminate marked CD20-positive B-cells. Stem cells (B-cell progenitors, those cells that give rise to B-cells) in bone marrow do not have the CD20 protein. B-cells usually regenerate after Rituxan treatment and return to normal levels in about 12 months for most patients.

 blog it

Comments

Popular posts from this blog

#StemCell #Transplant▶ #SocialCurrentSee®

Canswer♥Worth®▶ #SocialCurrentSee®

#MCL?▶ #SocialCurrentSee

Privacy Notice

Privacy Notice: The sites and blogs of ALTACITIES conform to these PRIVACY PRACTICES.